摘要
目的:探讨注射用母牛分枝杆菌对支气管哮喘病人的辅助治疗作用。方法:初次诊断的轻度持续或中度持续支气管哮喘病人34例,随机分为2组。观察组19例,予沙美特罗替卡松(50／250μg,吸入,bid)联合母牛分枝杆菌22．5μg,im,q 10 d。对照组15例,除不用母牛分枝杆菌外,余同观察组。疗程均为3 mo,治疗前后观察血清细胞因子和肺功能水平。结果:2组治疗后白细胞介素4(IL-4)、白细胞介素5(IL-5)、免疫球蛋白E(IgE)下降,干扰素γ(IFN-γ)上升,但仅观察组中IL-5[下降(46±s 13)ng·L^(-1)]和IgE[下降(86±43)IU·L^(-1)]变化有非常显著意义(P＜0．01)。2组用力肺活量和第1秒用力呼气量变化无显著差异(P＞0．05)。观察组治疗后每日最大呼气流量有所上升,治疗mo 2、3与对照组比较,差异非常显著(P＜0．01)。结论:注射用母牛分枝杆菌可促进Th 1型细胞因子分泌,抑制Th 2型细胞因子分泌,调节Th 1／Th 2平衡;并可能在一定程度上减轻气道阻力,对支气管哮喘病人具有明显辅助治疗作用。
AIM： To explore the assisted therapeutic effect of Mycobacterium vaccae （M.vaccae） on asthmatic patients. METHODS： Thirty-four asthmatic patients in mild or moderate persistent state were randomly enrolled into two groups： observation group （n = 19） and control group （n = 15） . The patients in observation group inhaled salmeterol xinafoate and flulieasone propionate （50/250 μg, bid） and intramuscular injection of M.vaccae （22.5 μg, q 10 d） The patients in control group only used salmetrol xinafoate and flulieasone propionate. The levels of IFN-γ, IL-4, IL-5, IgE in serum and lung function were determined before and after the treatment with a course of 3 months for both groups. RESULTS： After the drug intervention in two groups, the level of IFN-γ increased and those of IL-4, IL-5 and IgE decreased. In observation group, the levels of IL-5 deceased （46 ＋ s 13） ng·L^-1 （P 〈 0.01） and IgE deceased （86 ＋ 43） IU·L^-1 （P 〈 0.01） .There 0.05） signifi were no significant different in levels of FVC and FEV1 of lung function changes between two groups （P 〉 . In observation group, the levels of PEF in 2nd and 3rd month increased than those in 1 st month, with cant difference compared to those in control group at the same time （P 〈 0.01 ） . CONCLUSION： M.vaccae can provide assisted therapeutic effect on asthmatic patients, with contribution of the secretion of Thl cytokines, restraining the secretion of Th2 cytokines significantly, some extent lowing down the air way resistance. regulating the balance of Thl/Th2 and simultaneously to
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第5期375-377,共3页
Chinese Journal of New Drugs and Clinical Remedies
